[Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"].
We studied the clinical significance of serum prostate specific antigen (PSA) ratio: free-PSA/total-PSA and free-PSA/complex-PSA to discriminate between prostate cancer (PC) and prostate benign disease (non-PCa) by using total-PSA, alpha 1-antichymotrypsin complexed (complex)-PSA and free-PSA enzyme-linked immunosorbent assay (ELISA) kits newly developed at EIKEN Chemical Co, Ltd. Fre-PSA and complex-PSA ELISA kits demonstrated high sensitivity and specificity. Total-PSA ELISA kit also demonstrated equimolarity for free-PSA and complex-PSA. On the total-PSA range of 4-10 ng/ml, free-PSA/total-PSA% (f/t%) and free-PSA/complex-PSA% (f/c%) were very useful to discriminate between PCa and non-PCa by receiver operating characteristic curve analysis as well as PSA density (PSA-D) but not free-PSA level. F/t% and f/c% were even useful to discriminate early stage PCa (i.e. A1 or B0) from non-PCa by the Mann-Whitney U-test.
Imai
K
K
Atagawa Onsen Hospital.
Yamanaka
H
H
Kubota
Y
Y
Miki
M
M
Ito
T
T
Akaza
H
H
Uchida
K
K
Egawa
S
S
Kuriyama
M
M
Watanabe
H
H
Okihara
K
K
Kotake
T
T
Usami
M
M
Arai
Y
Y
Maeda
H
H
Sagiyama
K
K
Saito
Y
Y
Sakai
H
H
Shida
K
K
D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D006801:Humans; D008297:Male; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D012680:Sensitivity and Specificity; D015842:Serine Proteinase Inhibitors / Q000097:blood*; D000514:alpha 1-Antichymotrypsin / Q000097:blood*
D011933:Reagent Kits, Diagnostic; D015842:Serine Proteinase Inhibitors; D000514:alpha 1-Antichymotrypsin; D017430:Prostate-Specific Antigen